Agios Pharmaceuticals Inc (AGIO) 118.55 $AGIO
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness
at The Street - Wed Feb 11, 7:14PM CST
Lots of investors are worried about Europe, Cramer says, but you don't have to be.
KMI: 41.97 (+0.21), ACHC: 63.20 (-0.45), FLEX: 12.05 (-0.09), GE: 25.15 (+0.26), BBT: 38.28 (-0.04), AWAY: 29.68 (+0.11), XOM: 93.37 (+1.00), KEY: 14.11 (-0.08), INTC: 34.36 (+0.23), AFFX: 11.45 (+0.02), TWX: 83.87 (+0.56), PEP: 99.13 (-1.14), AEP: 57.83 (-0.15), ETP: 60.17 (+0.96), CMG: 674.89 (+4.60), QLYS: 47.95 (+1.46), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), HSIC: 143.18 (+0.72), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), CY: 14.76 (+0.01), SWKS: 81.85 (-0.57), PWR: 28.76 (-0.10), FB: 75.74 (-0.49), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), BA: 149.73 (+1.64), HPQ: 38.56 (+0.19), RAD: 8.34 (+0.25), CELG: 115.88 (+0.16), ZTS: 45.46 (-0.33), UA: 73.76 (-0.19), AA: 15.81 (+0.16), GILD: 101.90 (+1.10), STI: 41.57 (+0.01), GM: 37.62 (-0.40), AGIO: 118.55 (+0.11), CRL: 73.61 (-0.33), FSL: 37.53 (+2.83), VIAB: 68.98 (+1.27), CL: 70.08 (+0.23)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AMKR: 8.90 (-0.02), HNNA: 24.40 (+0.40), MU: 31.85 (-0.09), MATR: 7.07 (-0.12), EPRS: 7.67 (+0.67), MFLX: 14.99 (+0.16), AIRT: 19.45 (+0.39), GFN: 9.20 (+0.25), LAKE: 10.18 (+0.89), QLYS: 47.95 (+1.46), YDLE: 13.07 (+1.14), AGIO: 118.55 (+0.11), CBMG: 24.32 (-1.17)
Agios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015
GlobeNewswire - Tue Feb 10, 8:07AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Tuesday, February 17, 2015 at 8:30 a.m. EST to report its fourth quarter and full year 2014 financial results and discuss recent business activities.
AGIO: 118.55 (+0.11)
7 Companies We'd Buy and Hold for the Next 20 Years
Motley Fool Staff - Motley Fool - Fri Feb 06, 2:11PM CST
At The Motley Fool, we take a long-term view on investing. With that in mind, we asked seven of our analysts for their favorite stocks to hold for the next 20 years and beyond. Here's what they had to say. One company I'm interested in buying and...
BLUE: 90.70 (+0.93), TD: 44.57 (+0.14), PFE: 34.64 (-0.23), MO: 54.76 (-0.78), WM: 51.29 (-1.41), CELG: 115.88 (+0.16), PM: 82.87 (-0.82), V: 269.63 (-1.28), BAX: 70.39 (+0.31), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), MA: 87.14 (-0.38)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
Agios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11
GlobeNewswire - Tue Feb 03, 7:30AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the 2015 Leerink Global Healthcare Conference in New York on Wednesday, February 11, 2015 at 3:30 p.m. EST.
AGIO: 118.55 (+0.11)
The Top Healthcare Stock to Buy in February
Motley Fool Staff, Dan Caplinger, Todd Campbell, and Cheryl Swanson - Motley Fool - Sun Feb 01, 5:54AM CST
No one knows whether a stock is going to pop or drop in any given month or year, but our Motley Fool contributors say specific catalysts could move each of these three stocks higher over the next month, and that might be reason for investors to...
BLUE: 90.70 (+0.93), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), UNH: 109.44 (-0.40), AGIO: 118.55 (+0.11), CELG: 115.88 (+0.16)
3 Biotech Giants That Shouldn't Pay a Dividend
Motley Fool Staff, Leo Sun, Todd Campbell, and Cheryl Swanson - Motley Fool - Sat Jan 31, 7:04AM CST
It's been shown that dividend-paying stocks outperform their non-dividend paying counterparts, but focusing on dividends may not be the best strategy when it comes to big biotech stocks. Read on to learn why three Motley Fool contributors don't think...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), AGIO: 118.55 (+0.11), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)
Celgene Corp.'s Expanding Margins
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 29, 1:46PM CST
Celgene 's fourth-quarter earnings can be a bit of a snoozer because the company typically reports preliminary revenue and earnings numbers at JP Morgan 's healthcare conference earlier in January. This year was no different, but we did get some...
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
5 Cant-Miss Reasons Why Celgene Corporation Could Soar
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 26, 7:04AM CST
Source: Celgene Corporation Celgene Corporation 's slate of top selling medicines already makes it one of biotech's biggest success stories, but Celgene's recent long-term forecast suggests that the company's best days are ahead of it. Here are...
BLUE: 90.70 (+0.93), JNJ: 99.62 (+1.18), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
3 High-Flying Health Care Stock IPOs To Watch In 2015
at Investor's Business Daily - Wed Jan 21, 4:09PM CST
Judging by the recent price action of three health care names in today's IPO Leaders screen, the market is optimistic about future growth prospects. When an IPO prices below its proposed range, it's usually because of soft demand. But that wasn't the...
ALDR: 26.06 (+0.18), PRXL: 62.91 (-0.18), ILMN: 198.54 (+1.81), AGIO: 118.55 (+0.11), PRAH: 27.19 (+0.31), BMY: 60.04 (+0.56), ICLR: 60.01 (+0.38)
8 Biotech Stock Controversies Emerging From 'JPM15' Conference
at The Street - Tue Jan 20, 9:18AM CST
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), SRPT: 12.76 (+0.11), AGIO: 118.55 (+0.11)
The Week That Was: Healthcare Outlook Remains Excellent
Leonard Yaffe - at Seeking Alpha - Tue Jan 20, 8:44AM CST
BLUE: 90.70 (+0.93), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), CVS: 102.63 (-0.37), AGIO: 118.55 (+0.11), ARDX: 17.14 (+0.71), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Jim Cramer on Stocks: Here Are the Two Best CEOs You Can Bank On
at The Street - Wed Jan 14, 9:06AM CST
They're both named Bob.
DIS: 104.17 (+0.59), AGIO: 118.55 (+0.11), CELG: 115.88 (+0.16)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
GlobeNewswire - Mon Jan 12, 3:11PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act. Agios is webcasting its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference today at 2:30 p.m. PST (5:30 p.m. EST). The presentation will be followed by a webcast of its question and answer session at 3:00 p.m. PST (6:00 p.m. EST).
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), CELGZ: 3.17 (-0.04)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.96 (-0.03), BLCM: 20.00 (-0.81), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), CLDX: 20.97 (+0.53), CALA: 16.11 (+0.62), AGIO: 118.55 (+0.11)
Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:35AM CST
Agios Pharmaceuticals has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
AGIO: 118.55 (+0.11)
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness
at The Street - Wed Feb 11, 7:14PM CST
Lots of investors are worried about Europe, Cramer says, but you don't have to be.
KMI: 41.97 (+0.21), ACHC: 63.20 (-0.45), FLEX: 12.05 (-0.09), GE: 25.15 (+0.26), BBT: 38.28 (-0.04), AWAY: 29.68 (+0.11), XOM: 93.37 (+1.00), KEY: 14.11 (-0.08), INTC: 34.36 (+0.23), AFFX: 11.45 (+0.02), TWX: 83.87 (+0.56), PEP: 99.13 (-1.14), AEP: 57.83 (-0.15), ETP: 60.17 (+0.96), CMG: 674.89 (+4.60), QLYS: 47.95 (+1.46), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), HSIC: 143.18 (+0.72), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), CY: 14.76 (+0.01), SWKS: 81.85 (-0.57), PWR: 28.76 (-0.10), FB: 75.74 (-0.49), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), BA: 149.73 (+1.64), HPQ: 38.56 (+0.19), RAD: 8.34 (+0.25), CELG: 115.88 (+0.16), ZTS: 45.46 (-0.33), UA: 73.76 (-0.19), AA: 15.81 (+0.16), GILD: 101.90 (+1.10), STI: 41.57 (+0.01), GM: 37.62 (-0.40), AGIO: 118.55 (+0.11), CRL: 73.61 (-0.33), FSL: 37.53 (+2.83), VIAB: 68.98 (+1.27), CL: 70.08 (+0.23)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AMKR: 8.90 (-0.02), HNNA: 24.40 (+0.40), MU: 31.85 (-0.09), MATR: 7.07 (-0.12), EPRS: 7.67 (+0.67), MFLX: 14.99 (+0.16), AIRT: 19.45 (+0.39), GFN: 9.20 (+0.25), LAKE: 10.18 (+0.89), QLYS: 47.95 (+1.46), YDLE: 13.07 (+1.14), AGIO: 118.55 (+0.11), CBMG: 24.32 (-1.17)
Agios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015
GlobeNewswire - Tue Feb 10, 8:07AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will host a conference call and live webcast on Tuesday, February 17, 2015 at 8:30 a.m. EST to report its fourth quarter and full year 2014 financial results and discuss recent business activities.
AGIO: 118.55 (+0.11)
7 Companies We'd Buy and Hold for the Next 20 Years
Motley Fool Staff - Motley Fool - Fri Feb 06, 2:11PM CST
At The Motley Fool, we take a long-term view on investing. With that in mind, we asked seven of our analysts for their favorite stocks to hold for the next 20 years and beyond. Here's what they had to say. One company I'm interested in buying and...
BLUE: 90.70 (+0.93), TD: 44.57 (+0.14), PFE: 34.64 (-0.23), MO: 54.76 (-0.78), WM: 51.29 (-1.41), CELG: 115.88 (+0.16), PM: 82.87 (-0.82), V: 269.63 (-1.28), BAX: 70.39 (+0.31), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), MA: 87.14 (-0.38)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
Agios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11
GlobeNewswire - Tue Feb 03, 7:30AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the 2015 Leerink Global Healthcare Conference in New York on Wednesday, February 11, 2015 at 3:30 p.m. EST.
AGIO: 118.55 (+0.11)
The Top Healthcare Stock to Buy in February
Motley Fool Staff, Dan Caplinger, Todd Campbell, and Cheryl Swanson - Motley Fool - Sun Feb 01, 5:54AM CST
No one knows whether a stock is going to pop or drop in any given month or year, but our Motley Fool contributors say specific catalysts could move each of these three stocks higher over the next month, and that might be reason for investors to...
BLUE: 90.70 (+0.93), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), UNH: 109.44 (-0.40), AGIO: 118.55 (+0.11), CELG: 115.88 (+0.16)
3 Biotech Giants That Shouldn't Pay a Dividend
Motley Fool Staff, Leo Sun, Todd Campbell, and Cheryl Swanson - Motley Fool - Sat Jan 31, 7:04AM CST
It's been shown that dividend-paying stocks outperform their non-dividend paying counterparts, but focusing on dividends may not be the best strategy when it comes to big biotech stocks. Read on to learn why three Motley Fool contributors don't think...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), AGIO: 118.55 (+0.11), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)
Celgene Corp.'s Expanding Margins
Brian Orelli, The Motley Fool - Motley Fool - Thu Jan 29, 1:46PM CST
Celgene 's fourth-quarter earnings can be a bit of a snoozer because the company typically reports preliminary revenue and earnings numbers at JP Morgan 's healthcare conference earlier in January. This year was no different, but we did get some...
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
5 Cant-Miss Reasons Why Celgene Corporation Could Soar
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 26, 7:04AM CST
Source: Celgene Corporation Celgene Corporation 's slate of top selling medicines already makes it one of biotech's biggest success stories, but Celgene's recent long-term forecast suggests that the company's best days are ahead of it. Here are...
BLUE: 90.70 (+0.93), JNJ: 99.62 (+1.18), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)
3 High-Flying Health Care Stock IPOs To Watch In 2015
at Investor's Business Daily - Wed Jan 21, 4:09PM CST
Judging by the recent price action of three health care names in today's IPO Leaders screen, the market is optimistic about future growth prospects. When an IPO prices below its proposed range, it's usually because of soft demand. But that wasn't the...
ALDR: 26.06 (+0.18), PRXL: 62.91 (-0.18), ILMN: 198.54 (+1.81), AGIO: 118.55 (+0.11), PRAH: 27.19 (+0.31), BMY: 60.04 (+0.56), ICLR: 60.01 (+0.38)
8 Biotech Stock Controversies Emerging From 'JPM15' Conference
at The Street - Tue Jan 20, 9:18AM CST
The J.P. Morgan Healthcare Conference is in the rear-view mirror, but issues, controversies and questions raised during the annual gathering of the biotech sector tribe will linger through the year.
BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), SRPT: 12.76 (+0.11), AGIO: 118.55 (+0.11)
The Week That Was: Healthcare Outlook Remains Excellent
Leonard Yaffe - at Seeking Alpha - Tue Jan 20, 8:44AM CST
BLUE: 90.70 (+0.93), KITE: 62.59 (+0.82), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), CVS: 102.63 (-0.37), AGIO: 118.55 (+0.11), ARDX: 17.14 (+0.71), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Jim Cramer on Stocks: Here Are the Two Best CEOs You Can Bank On
at The Street - Wed Jan 14, 9:06AM CST
They're both named Bob.
DIS: 104.17 (+0.59), AGIO: 118.55 (+0.11), CELG: 115.88 (+0.16)
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Jan 13, 12:00AM CST
A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week
INCY: 75.94 (+0.28), OPHT: 51.11 (+0.12), AGIO: 118.55 (+0.11), OSUR: 8.13 (+0.06), XNPT: 6.69 (-0.21)
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
GlobeNewswire - Mon Jan 12, 3:11PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act. Agios is webcasting its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference today at 2:30 p.m. PST (5:30 p.m. EST). The presentation will be followed by a webcast of its question and answer session at 3:00 p.m. PST (6:00 p.m. EST).
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), CELGZ: 3.17 (-0.04)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.96 (-0.03), BLCM: 20.00 (-0.81), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), CLDX: 20.97 (+0.53), CALA: 16.11 (+0.62), AGIO: 118.55 (+0.11)
Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:35AM CST
Agios Pharmaceuticals has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
AGIO: 118.55 (+0.11)
